Testmate Health’s Post

Beyond its role in bodily functions, #urine is more than just a remedy for a jellyfish sting 🪼 it holds untapped potential across multiple fields, from organic fertilizers to non-invasive methods for disease detection 🔬 In this article, we highlight 10 promising European startups that are leveraging the power of urine for innovative and practical solutions: Amber Therapeutics, AssistMe, EG 427 , inContAlert, Jude, Testmate Health, The Blue Box Biomedical Solutions, TOOPI ORGANICS, Usense, VunaNexus AG https://lnkd.in/djS_eMQj

ZBiotics Secures $12M Series A Funding to Advance Novel Probiotics Developer of the world’s first genetically modified probiotics, ZBiotics has secured $12 million in series A funding round to meet the soaring consumer demand, support retail expansion, and drive research and development to bring more products to the market. Co-founded in 2016 by Zachary Abbott and Stephen Lamb JD, the biotechnology startup develops genetically engineered probiotics designed to augment the functioning of human body systems, bringing new functionality to help the body handle everyday chemicals and contaminants. The oversubscribed round was spearheaded by Springtide Capital and included participation from other investors, including Seamless Capital LP, Access Capital Partners, Seaside Ventures, and Goat Rodeo Capital. Read more: https://lnkd.in/g9tEZB-s #fundingnews #FundingOpportunity #StartupFunding #StartupSuccess #HealthcareNews #Biotechnology #HealthcareFunding #nextdigitalhealth #Wi4 #vineetagrawal

Sweden's Ironic Biotech secures €1M in a pre-seed round!💰 The startup aims to alleviate iron deficiency and anemia affecting 2 billion individuals worldwide. It has discovered a new generation of plant-derived proteins rich in bioavailable iron, produced via precision fermentation, promising no side effects. These proteins offer potential as ingredients in food or supplements. Here’s how the startup will use the funds: https://lnkd.in/gFZ6JUuu Nélida Leiva Eriksson, Eskil Åhlin, Nordic Foodtech VC, Louise Rørbæk Heiberg

Discover the groundbreaking work of Brightseed, a San Francisco-based startup in the iSelect Fund portfolio, revolutionizing the field of nutrition with AI and machine learning. Led by founders Sofia Elizondo, Dr. Lee Chae, and Dr. Jim Flatt, Brightseed unveils the hidden potential in plant and fungal kingdoms to address health challenges. 💡 How does it work? Brightseed's AI-powered Forager platform identifies plant-based compounds associated with health benefits, predicting their potential and optimizing sourcing or production at commercial scale. The result? Innovative products like their first offering sourced from upcycled hemp hulls, containing bioactives supporting gut health, liver health, and weight management. 🌍 Collaborations and Impact Working with major partners from CPG, ingredients, and pharmaceutical industries, Brightseed is making waves in product discovery. Learn from Dr. Jim Flatt's insights, drawn from 30 years in biomanufacturing, as he reflects on lessons learned and the importance of technology readiness. 🚀 From Concept to Reality Explore how Brightseed's unique approach, blending AI with traditional methods and clinical testing, accelerates the translation of discoveries into commercially viable products. The founders' complementary skills and long-term collaboration contribute to the company's success. 🌿 Future Focus Brightseed is focusing on addressing unmet health needs in areas like gut health, metabolic health, and cognitive function. Stay tuned for clinical studies and new bioactive introductions that promise major breakthroughs in health and nutrition. Read the full interview with Dr. Jim Flatt on AFN: https://lnkd.in/gMGsF4ye #Brightseed #iSelectFund #NutritionInnovation #AIinHealth #BioactiveDiscovery #HealthTech #InnovationInNutrition #foodishealth

🇸🇪🩸 Ironic Biotech raised €1M pre-seed funding for precision fermentation-based plant-derived proteins to address iron deficiency Up to 25% of the global population suffers from iron deficiency, which causes severe symptoms and goes widely undetected. Ironic Biotech aims to help 2 billion people prevent and recover from iron deficiency and anaemia, noting a performance gap largely affecting women due to natural iron loss. The Lund-based biotech startup plans to use the funding for further R&D, expand its patent portfolio, and optimise the production process. It's currently looking for partners in the food and food supplement industries. Ironic Biotech's patented compounds offer a solution to the downsides of current iron supplements and meat-based sources, with no side effects, room temperature storage, and high absorption rates. These qualities make them ideal for those on plant-based diets or with iron deficiencies. Nélida Leiva Eriksson ✉️ Hungry for more updates on biotech shaping the future of food? Devour the free subscription: betterbioeconomy.com

For centuries, willow bark was used for pain relief until Bayer isolated its active ingredient in the 1800s, creating Aspirin. Many modern #medicines, about 40%, have roots in ancient remedies, but only a fraction of natural compounds have been explored for their medicinal potential. Viswa Colluru, PhD, formerly of Recursion Pharmaceuticals, founded Enveda Biosciences in 2019 to expedite discovery new medicines using #AI. Enveda's AI taps into global #data on plant usage across cultures, identifying promising plants for further #testing. The #company’s database links 38,000 medicinal plants to 12,000 diseases and symptoms. Enveda's approach is proving #successful, with two drugs for skin conditions and inflammatory bowel diseases set for clinical trials. The #company recently raised $55 million in Series B2 funding, totaling $230 million in capital, with investors including #Microsoft and The Nature Conservancy. Colluru emphasized the vast, untapped potential of natural compounds beyond well-known substances like cannabis and psychedelics. Enveda is focused on the broader chemical diversity found in nature, aiming to discover many potential new drugs. #startup #startupbusiness #Accessibility #Innovation #SustainableLiving #SmartTechnology #FutureOfWork  #FutureBuilding If you spot any inaccuracies, please let us know so we can correct them. Your feedback helps us improve. Thanks!

🚀 Big News: LØUCO is Launching Our First Fundraising Round! We’re thrilled to announce that LØUCO is officially opening our £250k fundraising round through FounderCatalyst as we gear up for our November launch! 🚀💡 This is a unique investment opportunity to be part of something transformative in the plant-based protein industry. Our doctor-led, plant-based protein powders are designed specifically for women’s physiology, with a focus on hormone health. Unlike many products on the market, our formulas are free from sweeteners, added sugars, ultra-processed ingredients, and harmful bulking agents—clean, purposeful, and truly effective. 💡 Why Invest in LØUCO? 🚀 Innovative Product: 3 years in the making, developed to meet the unmet needs of women’s health. 🚀 High-Growth Market: Plant-based protein is booming, and we're tapping into a segment that remains under-served. 🚀 Mission-Driven: We’re committed to improving women’s health from within, aligning profit with purpose. 💼 Key Details: Target Raise: £250k Timeline: 8 weeks Funds Utilisation: Supporting product refinement, strategic hires, community building, and high-impact marketing to drive growth. If you’re passionate about investing in the future of women's health and clean, science-backed nutrition, we’d love to connect! DM me or email info@louco.co for more information. Let’s fuel the future of wellness together! 🌟 #InvestmentOpportunity #StartupLife #WomensHealth #PlantBased #ImpactInvesting

Sova Health, a pioneering startup in gut health, has secured $1 million in a seed funding round. This round was co-led by global early-stage venture capital firms Antler, Accelerating Asia Ventures (Singapore), Practical VC (USA), and VC Grid & Venture Catalysts (India). Additional investors include Quadrant Consumer Products and Midas Capital (Baheti Family Office), along with several prominent angel investors who remain undisclosed. The newly acquired funds will be allocated to product development, enhancing Sova Health's range of gut health solutions. The startup also plans to grow its team and expand its geographical market presence. Part of the investment will be directed towards launching a clinical trial for Sova Health’s Digital Therapeutics (DTx) program, reinforcing the company’s dedication to scientific research and product effectiveness. Founded by Tanveer Singh and Max Kushnir, Sova Health addresses various gut health issues such as irritable bowel syndrome (IBS), acidity, constipation, and bloating. Sova Health offers direct-to-consumer gut microbiome tests and a proprietary line of probiotic supplements. Additionally, they provide customized gut health programs tailored for individuals with gastrointestinal conditions like IBS, IBD, GERD, Crohn’s Disease, and chronic acidity. Their comprehensive approach integrates gut biome diagnostics, probiotics, and nutritional therapy to alleviate symptoms and promote remission. Prior to this seed round, Sova Health received pre-seed funding from notable investors including Goodwater Capital, Brinc, IIMA Ventures, and Stanford Angels & Entrepreneurs. #SovaHealth #GutHealth #HealthTech #SeedFunding #FundingAlert #Funding #FundraiserAlert #VentureCapital #Probiotics #Microbiome #DigitalTherapeutics #IBS #IBD #GERD #CrohnsDisease #Constipation #Acidity #NutritionalTherapy #ProductDevelopment #HealthInnovation #ClinicalTrials #Investment #HealthStartups #AngelInvestors #AllBoutCorps

https://lnkd.in/dzks5fp2 Prolific Machines snags $55 million to improve biomanufacturing of cultivated meats and medicines. Prolific Machines has wagered that the precision use of light can make cultivated fish, poultry and beef a low-cost, mass-market reality. The Emeryville, Calif.-based biotech startup raised $55 million to commercialize its photo molecular biology platform, which it claims can significantly reduce the costs of producing cultivated meats, pharmaceuticals and nutritional and therapeutic proteins. Prolific’s biomanufacturing platform has potential “to unlock profound impact in both human and environmental health across multiple industries,” said Komal Mistry-Mehta of Ki Tua Fund, the venture arm of New Zealand-based publicly-traded dairy cooperative Fonterra Co-operative Group. That includes whole cuts of cultured meat, antibodies to treat diseases, and other bio-manufactured solutions. The Series B round, which included convertible notes, was led by Ki Tua alongside Breakthrough Energy Ventures, Footprint Coalition Ventures, Mayfield, SOSV, Shorewind Capital, In-Q-Tel and family office Darco Capital, among others. Lighting the way. Prolific Machines’ technology is a twist on optogenetics, which uses light to control the activity of living cells. The experimental field has been the domain of neuroscientists seeking to treat autism, drug abuse and depression. Prolific says its proprietary AI-assisted software, genetic tools and hardware platform can shape and influence “virtually any cell function in any cell type.” The company plans to license its technology to other companies to “more efficiently biomanufacture high-value bioproducts.”

🚀 Big News: LØUCO is launching their first fundraising round! Thrilled to announce that LØUCO is officially opening their £250k fundraising round through FounderCatalyst as we gear up for a November launch! 🚀💡 This is a unique investment opportunity to be part of something transformative in the plant-based protein industry. Louco's doctor-led, plant-based protein powders are designed specifically for women’s physiology, with a focus on hormone health. Unlike many products on the market, their formulas are free from sweeteners, added sugars, ultra-processed ingredients, and harmful bulking agents—clean, purposeful, and truly effective. 💡 Why Invest in LØUCO? 🚀 Innovative Product: 3 years in the making, developed to meet the unmet needs of women’s health. 🚀 High-Growth Market: Plant-based protein is booming, and we're tapping into a segment that remains under-served. 🚀 Mission-Driven: We’re committed to improving women’s health from within, aligning profit with purpose. 💼 Key Details: Target Raise: £250k Timeline: 8 weeks Funds Utilisation: Supporting product refinement, strategic hires, community building, and high-impact marketing to drive growth. If you’re passionate about investing in the future of women's health and clean, science-backed nutrition please DM me or email info@louco.co for more information. Let’s fuel the future of wellness together! 🌟 Throwback to the Unrest Demo Day where Co-Founder Dr Jo Mennie pitched for LØUCO. Rachel Prince Dr Jo Mennie #InvestmentOpportunity #StartupLife #WomensHealth #PlantBased #ImpactInvesting